Manufacturing of life-enhancing medicines boosted by new government funding

22 Nov 2018

Patients could receive faster treatment following boost to streamline the production of medicines and treatments.

Patients could soon receive faster treatment thanks to a multimillion pound government boost to streamline the production of medicines and treatments, including those used to treat blood cancers and inherited disorders.

Manufacturing of life-enhancing medicines boosted by new government funding

Companies in Northumberland, Oxford and London will adopt new digital technologies, such as artificial intelligence, to support the manufacture of next-generation medicines and treatments.

The £4.3 million funding aims to create more efficient and innovative methods for manufacturing medicines. The challenge works to set the UK apart as a leader with greater capacity for manufacture of safe, affordable and effective therapies.

Life Sciences Minister Lord Henley said: "New technology can help us live longer, healthier lives and the new projects announced today will improve the speed and accuracy with which medicines get to the people that need them.

"Advances in technology can help us address the challenges that an ageing society presents and we are backing the technologies of tomorrow in our modern Industrial Strategy, with the biggest increase in public research and development investment in UK history."

The three individual projects are:

  • Arc Trinova in Northumberland will use new technologies to speed up the process of the production of patient-specific medicines; it is currently a timely process dispensing individual doses from bulk because of the careful handling, labelling and batch release processes.
  • Oxford Biomedica will look to dramatically reduce the supply time for manufacturing by using a new digital and robotics framework to increase capacity, reduce waste and cut costs.
  • Autolus in London will look to avoid mix-ups of complex medicines on the supply chain by developing a computer-based system that will constantly monitor the operation, making adjustments to timing, co-ordination and production where necessary, improving the efficiency of the whole system and working at a pace that human operators cannot imitate.
  • One year on from the launch of the Industrial Strategy, this £7.3 million investment is the latest commitment from the £180 million Industrial Strategy Challenge Fund (ISCF) dedicated to leading-edge Medicines Manufacturing.

    Taking steps to improve patient access to life-saving treatments and medicines, Advanced Therapy Treatment Centres, working across the UK, will support the roll-out of cell and gene therapies as clinical trials show them to be safe and cost-effective. The centres bring together expert clinicians, researchers, scientists, developers and private companies to demonstrate how the therapies have impact on patients’ lives.

    Advanced therapies, including cell and gene therapies, represent the next generation of therapies that have the potential to offer treatments for a number of conditions including some blood cancers and inherited conditions for which there are currently limited treatment options.

    UK Research and Innovation (UKRI) is responsible for managing the Industrial Strategy Challenge Fund, which funds the winners of the Medicines Manufacturing Challenge.

    Dr Ian Campbell, Interim Executive Chair, Innovate UK for UKRI, said: "The projects announced today will bring real benefits to patients and boost the knowledge economy as part of the government’s modern Industrial Strategy. This is vital for the UK as a global leader in the development of advanced therapies and medicine manufacturing."

    Read More

    Related news

    Legacy ramps up preparations for new Russian track and trace sterilisation regulations

    Legacy ramps up preparations for new Russian track and trace sterilisation regulations

    18 Jul 2019

    Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.

    Read more 
    Combination technique improves polysaccharide characterization

    Combination technique improves polysaccharide characterization

    17 Jul 2019

    The AF4-MALS-RI method makes possible the accurate determination of molecular weight distribution of polysaccharide macromolecules.

    Read more 
    Lubrizol integrates personal, home and health care divisions

    Lubrizol integrates personal, home and health care divisions

    16 Jul 2019

    The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.

    Read more 
    Bosch finds buyers for its packaging machinery business

    Bosch finds buyers for its packaging machinery business

    16 Jul 2019

    CVC Capital Partners to " take the business forward in the years ahead, and to make it even more competitive".

    Read more 
    New state-of-the-art cleanroom boosts production of anticancer drugs

    New state-of-the-art cleanroom boosts production of anticancer drugs

    15 Jul 2019

    The GMP facility has been specifically designed to deliver the next generation of anticancer blockbuster ADC drugs for patients globally.

    Read more 
    Colorcon chooses the Netherlands for new starch manufacturing plant

    Colorcon chooses the Netherlands for new starch manufacturing plant

    12 Jul 2019

    The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.

    Read more 
    GSK opens new continuous manufacturing facilities in Singapore

    GSK opens new continuous manufacturing facilities in Singapore

    11 Jul 2019

    Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

    Read more 
    Eisai collaborates with University of Dundee on cancer drug discovery

    Eisai collaborates with University of Dundee on cancer drug discovery

    10 Jul 2019

    It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

    Read more 
    Onyx Scientific makes strategic investment in commercial API licence

    Onyx Scientific makes strategic investment in commercial API licence

    10 Jul 2019

    Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

    Read more 
    I Holland to share the science behind tool maintenance

    I Holland to share the science behind tool maintenance

    9 Jul 2019

    Proper maintenance - rather than replacement - of compression tooling will improve profitability.

    Read more